What are the current guideline-recommended steps for diagnosing and managing pulmonary hypertension in an adult?

Pulmonary Hypertension: Guideline-Based Diagnostic and Management Approach

Hemodynamic Definition and Classification

Pulmonary hypertension is defined as mean pulmonary artery pressure ≥25 mmHg at rest, confirmed by right heart catheterization, which is mandatory for diagnosis. 1

Key Hemodynamic Categories

• Pre-capillary PH: Mean PAP ≥25 mmHg, PAWP ≤15 mmHg, and PVR >3 Wood Units 1
• Isolated post-capillary PH: Mean PAP ≥25 mmHg, PAWP >15 mmHg, DPG <7 mmHg and/or PVR ≤3 Wood Units 1
• Combined post- and pre-capillary PH: Mean PAP ≥25 mmHg, PAWP >15 mmHg, DPG ≥7 mmHg and/or PVR >3 Wood Units 1

Five Clinical Groups

1. Group 1 – Pulmonary Arterial Hypertension (PAH): Includes idiopathic, heritable (BMPR2, ALK1, EIF2AK4 mutations), drug/toxin-induced, and associated forms (connective tissue disease, congenital heart disease, portal hypertension, HIV, schistosomiasis) 1

2. Group 2 – PH due to left heart disease: Systolic/diastolic dysfunction, valvular disease 1

3. Group 3 – PH due to lung diseases/hypoxemia: COPD, interstitial lung disease, sleep-disordered breathing 1

4. Group 4 – Chronic thromboembolic PH (CTEPH) and other PA obstructions: Includes pulmonary angiosarcoma, arteritis, congenital PA stenoses 1

5. Group 5 – PH with unclear/multifactorial mechanisms: Sarcoidosis, hematologic disorders (chronic hemolytic anemia moved from Group 1 to Group 5), metabolic disorders 1

Diagnostic Algorithm

Step 1: Clinical Suspicion and Initial Screening

Transthoracic Doppler echocardiography is the first-line screening tool for any adult with unexplained dyspnea, exercise intolerance, syncope, or right ventricular strain. 2

High-Risk Populations Requiring Systematic Screening:

• Connective tissue disease, especially scleroderma spectrum (poor prognosis) 2
• Family history of PAH or BMPR2 mutation 2
• Portal hypertension (liver transplant candidates) 2
• Congenital heart disease 2
• HIV infection 2
• Prior venous thromboembolism 2
• Exposure to appetite suppressants, mitomycin-C, carfilzomib, carmustine, etoposide, cyclophosphamide, bleomycin 1, 2

Key Clinical Presentations:

• Syncope/presyncope occurs in ~40% of patients and warrants urgent workup 2
• Fatigue, weakness, chest pain each affect ~40% 2
• Accentuated pulmonary component of S2 at apex present in ~90% of idiopathic PAH 2
• Left parasternal lift (RV hypertrophy), RV S4 gallop (~38%), prominent jugular "a" waves 2
• Advanced disease: pulmonary regurgitation murmur, peripheral edema, hepatomegaly, ascites 2

Step 2: Echocardiography-Based Decision Pathway

The echocardiographic probability of PH determines the next diagnostic step:

"PH Unlikely" on Echo:

• No symptoms: No further workup needed 2
• Symptoms + risk factors: Echocardiographic follow-up 2
• Symptoms without risk factors: Evaluate alternative causes 2

"PH Possible" on Echo:

• No symptoms, no risk factors: Echocardiographic follow-up 2
• Symptoms + risk factors: Consider right heart catheterization 2
• Symptoms without risk factors: Evaluate alternatives; if symptoms ≥moderate severity, consider RHC 2

"PH Likely" on Echo:

• With symptoms (regardless of risk factors): Right heart catheterization mandatory 2
• Without symptoms (regardless of risk factors): Consider right heart catheterization 2

Step 3: Mandatory Right Heart Catheterization

Right heart catheterization is required at baseline for all patients in whom PAH is suspected to confirm diagnosis, assess prognosis, and guide therapy. 1, 2

Required Hemodynamic Measurements:

• Mean, systolic, and diastolic pulmonary artery pressures 2
• Right atrial pressure 2
• Pulmonary capillary wedge pressure 2
• Right ventricular pressure 2
• Cardiac output measured in triplicate (thermodilution or Fick method) 2

Step 4: Comprehensive Diagnostic Workup

All patients with unexplained PH must undergo ventilation/perfusion lung scan to exclude CTEPH—failure to perform this test can miss treatable disease. 2

Mandatory Imaging Studies:

• V/Q scan: Required in all unexplained PH to exclude CTEPH 2
• Contrast CT angiography: When CTEPH suspected 2
• High-resolution chest CT: Consider in all PH patients 2
• Chest radiography: May show enlarged central pulmonary arteries (right interlobar artery >15 mm in women, >16 mm in men), but normal film does not exclude PH 2

Laboratory Evaluation:

• Routine biochemistry, hematology, thyroid function 2
• Liver function tests (all patients) 2
• Serology for connective tissue disorders, HIV 2
• Pulmonary function testing and arterial blood gases 2
• Abdominal ultrasound to screen for portal hypertension 2

Critical Pitfall: Do not rely solely on chest radiography; a normal film cannot exclude early PH. 2

Contraindication: Open or thoracoscopic lung biopsy is not recommended in PAH patients. 2

Prognostic Assessment

WHO Functional Classification

The WHO Functional Class is the cornerstone of risk stratification and treatment decisions:

• Class I: No limitation of physical activity; ordinary activity does not cause undue dyspnea, fatigue, chest pain, or syncope 1, 3
• Class II: Slight limitation; comfortable at rest; ordinary activity causes symptoms 1, 3
• Class III: Marked limitation; comfortable at rest; less than ordinary activity causes symptoms 1, 3
• Class IV: Unable to carry out any physical activity without symptoms; dyspnea/fatigue may be present at rest; signs of right heart failure 1, 3

Comprehensive Risk Stratification

Better prognosis is indicated by:

• No clinical evidence of RV failure 1
• Slow rate of symptom progression 1
• No syncope 1
• WHO-FC I-II 1
• 6-minute walk distance >500 m (shorter <300 m indicates worse prognosis) 1
• Peak O2 consumption >15 mL/min/kg (worse if <12 mL/min/kg) 1
• Normal or near-normal BNP/NT-proBNP 1
• No pericardial effusion on echo 1
• TAPSE >2.0 cm, cardiac index >2.5 L/min/m², RAP <8 mmHg 1

Worse prognosis is indicated by:

• Advanced WHO-FC (III-IV) 2
• Reduced 6-minute walk distance 2
• Elevated right atrial pressure 2
• Significant RV dysfunction on imaging 2
• Approximately 15% mortality within one year despite modern therapy 2

Follow-Up Protocol

Reassessment should occur every 3-6 months using multiple parameters simultaneously:

Baseline Assessment (Prior to Therapy):

• Clinical assessment and WHO-FC 1
• ECG 1
• 6-minute walk test 1
• Cardiopulmonary exercise testing 1
• BNP/NT-proBNP 1
• Echocardiography 1
• Right heart catheterization 1

Every 3-6 Months:

• Clinical assessment and WHO-FC 1, 4
• 6-minute walk test 1, 4
• BNP/NT-proBNP 1, 4
• Echocardiography 1, 4

At Therapy Initiation/Changes or Clinical Worsening:

• All baseline assessments should be repeated 1
• Right heart catheterization should be performed 1

General Management Recommendations

Class I Recommendations (Must Do):

• Avoid pregnancy in all PAH patients 1, 4
• Immunization against influenza and pneumococcal infection 1, 4
• Diuretics for RV failure and fluid retention 1, 4
• Continuous long-term oxygen therapy when arterial PO2 <8 kPa (60 mmHg) 1, 4

Class IIa Recommendations (Should Consider):

• Supervised exercise rehabilitation for physically deconditioned patients 1, 4
• Psychosocial support 1, 4
• In-flight oxygen for WHO-FC III-IV or arterial PO2 <8 kPa 1
• Epidural over general anesthesia for elective surgery 1
• Oral anticoagulation (warfarin) for idiopathic PAH, heritable PAH, and anorexigen-associated PAH 1, 4

Class IIb Recommendations (May Consider):

• Oral anticoagulation in associated PAH (individualize based on bleeding risk) 1, 4
• Digoxin for atrial tachyarrhythmias to control ventricular rate 1

Class III Recommendations (Do Not Do):

• Excessive physical activity that leads to distressing symptoms 1
• Anticoagulation in PAH associated with portal hypertension (increased bleeding risk) 4

Urgent Referral Criteria

Immediate referral to a specialized pulmonary hypertension center is required for:

• Syncope 2
• Rapid symptom progression 2
• Overt right heart failure 2
• Suspected PAH or CTEPH 2
• Unexplained PH of uncertain etiology 2